Keep pulling the thread on Bryan Johnson.
Longevity-focused companies like BioAge often have to pivot to a traditional biotech model, focusing on a specific disease, to secure later-stage funding.
The NIH has experienced sudden budget cuts in the last year, creating a chaotic funding environment for academic researchers.
It is hypothesized that recent NIH funding cuts will lead to a reduction in the amount of intellectual property being translated out of universities within the next 3-4 years.
Legislation has been passed in Montana and is advancing in New Hampshire to expand eligibility under the federal Right to Try Act.
Life Biosciences is expected to begin recruiting for clinical trials on epigenetic reprogramming by the end of this year.
The FDA is open to the concept of treating aging as a clinical condition but requires the industry to establish validated surrogate endpoints for trials.
Bryan Armstrong's company, NewLimit, closed a $500 million funding round.
Dylan Livingston finds that mentioning Bryan Johnson in meetings on Capitol Hill is detrimental to his advocacy efforts for the longevity biotech industry.
Georgetown University has implemented budget cuts that have negatively impacted faculty hiring.
The Right to Try Act, passed during the first Trump administration, grants terminally ill patients access to experimental therapeutics.
Priyanka believes Bryan Johnson has been a net positive for the longevity field by increasing public awareness and attracting investment.
The venture capital fund Longevity Tech Fund has invested in more than 40 different companies in the longevity space.